Study of SCTC21C for IgA nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests an investigational drug (SCTC21C) for people with a type of autoimmune kidney disease called IgA nephropathy. It aims to see if the drug can reduce protein in the urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your kidney disease must be IgA nephropathy, confirmed by a kidney biopsy.
- You must be on a stable, maximum tolerated dose of ACE inhibitor or ARB (blood pressure medicines) for at least 12 weeks.
- Your kidney function (eGFR) must be 30 or higher (moderate or better).
- You must have significant protein in your urine (at least 1 gram per day).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called CM313 in people with IgA nephropathy, a kidney disease. It may help reduce protein in the urine, which is a sign of kidney damage.
This trial tests telitacicept in people with IgA nephropathy that has not responded well to standard care. It aims to reduce harmful kidney inflammation and protein leakage in the urine.
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
This phase 2a trial tests an experimental drug called RG002C0106 in people with primary IgA nephropathy. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This study tests an experimental drug called MY008211A for people with IgA nephropathy (a kidney disease). It aims to see if it can safely reduce protein in the urine and protect kidney function.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.